Legal News

PBM reform legislation has progressed further in Congress than ever before.

On October 3,2024, Texas Attorney General Ken Paxton issued the lawsuit, which involves Eli Lilly, Express Scripts, CVS Pharmacy, and other pharmaceutical entities.

Senators Ron Wyden and Sherrod Brown wrote a letter to the Federal Trade Commission calling to explore yet another PBM tactic impeding competition.

In its first move since the July interim report detailing pharmacy benefit manager practices, the FTC is now suing CVS Caremark, Express Scripts, and Optum Rx.

To further understand PBM market concentration, researchers separately analyzed commercial insurance, Medicare Part D, and Medicaid managed care market strategies of the 3 biggest PBMs.

Pharmacists can fill a role for patients, but without technology supporting workflows and reimbursement efforts, challenges will remain.

Through Surescripts, pharmacists can cut down on back-and-forth with prescribers’ offices, saving valuable time for patient care.

Inviting members of Congress into the pharmacy helps legislators experience first hand the value that pharmacists bring to their communities.

Bipartisan support—in a polarized Congress—underscores the importance of pharmacy benefit manager reform.

The American Pharmacists Association is dedicating further time and resources to its ongoing fight for federal PBM reform.

Participants were asked to rate their level of concern on 26 health topics.

Tom DePietro, PharmD, owner of DePietro’s Pharmacy in Dunmore, Pennsylvania, discussed his experience as an independent pharmacy owner working under the thumb of pharmacy benefit managers.

Our congressional representatives have plenty of interaction with PBM lobbyists. It’s time they hear from patients as well.

From expanding vaccination coverage to battling with PBMs, the community pharmacist has the ability to promote change like never before.

In a House Committee on Oversight and Accountability hearing, Democrats and Republicans took a bipartisan stance to question the role major PBMs play regarding rising drug costs in the US.

Steve Postal, JD, Director of Policy and Regulatory Affairs at the National Community Pharmacists Association (NCPA), sat down with Drug Topics to discuss Pharmacy Benefit Managers.

Steve Postal, JD, Director of Policy and Regulatory Affairs at the National Community Pharmacists Association (NCPA), discussed pharmacy benefit managers and vehicles necessary to induce reform.

House Bill (HB) 1993 seeks to increase PBM transparency and accountability in an effort to combat the rising cost of prescription drugs.

The FTC released its interim report detailing PBM practices, staggering market consolidation statistics, and the disparities between PBMs and their smaller competitors.

“Retail pharmacy is central to our future and to our overall customer and patient experience. It enables many other things, but it has to change,” said Walgreens CEO Tim Wentworth.

On the second anniversary of the overturning of Roe v Wade, check out recent coverage on abortion and contraceptive access.

Chris DesRochers, a pharmacy technician who works at a CVS in Wakefield, Rhode Island and is active in the recent organizing, discusses what motivated him and his coworkers to unionize.

Emergency department visits tripled by December 2022 compared with the pre-legalization period from January 2015 to September 2018.

Although the US Drug Enforcement Agency's (DEA) proposed reclassification of marijuana wouldn’t legalize the drug nationwide, it could shake up the current marijuana landscape.

In its ongoing campaign against “scope creep,” the American Medical Association argued that pharmacists don’t receive enough training. Physicians and pharmacists alike disagree.

The class action lawsuit against CVS Health, Caremark, and Aetna was announced earlier today.

Todd Eury of the Pharmacy Podcast Network is joined by Josh Bolin of the NABP to talk about DSCSA, what benefits it will provide, and how to make sure your pharmacy is ready when it goes into effect this November.

The act is currently set to go into effect in just over three months.

According to a spokesperson, the company is prepared to take the lawsuit to the Supreme Court.

The combination of Lynparza and abiraterone reduced the risk of disease progression or death by 76% vs. abiraterone alone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.